Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
E-pub ahead of print

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Research output: Contribution to journalReviewResearchpeer-review

  1. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiac procholecystokinin expression during haemodynamic changes in the mammalian heart

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Wavy multistratified amacrine cells in the monkey retina contain immunoreactive secretoneurin

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sebastian M Heimbürger
  • Natasha C Bergmann
  • Robert Augustin
  • Lærke S Gasbjerg
  • Mikkel B Christensen
  • Filip K Knop
View graph of relations

Accumulating evidence suggests that glucose-dependent insulinotropic polypeptide (GIP) in addition to its involvement in type 2 diabetic pathophysiology may be involved in the development of obesity and the pathogenesis of cardiovascular disease. In this review, we outline recent preclinical and clinical cardiovascular-related discoveries about GIP. These include chronotropic and blood pressure-lowering effects of GIP. Furthermore, GIP has been suggested to control vasodilation via secretion of nitric oxide, and vascular leukocyte adhesion and inflammation via expression and secretion of endothelin 1. Also, GIP seems to regulate circulating lipids via effects on adipose tissue uptake and metabolism of lipids. Lastly, we discuss how dysmetabolic conditions such as obesity and type 2 diabetes may shift the actions of GIP in an atherogenic direction, and we provide a perspective on the therapeutic potential of GIP receptor agonism and antagonism in cardiovascular diseases. We conclude that GIP actions may have implications for the development of cardiovascular disease, but also that the potential of GIP-based drugs for the treatment of cardiovascular disease currently is uncertain.

Original languageEnglish
JournalPeptides
ISSN0196-9781
DOIs
Publication statusE-pub ahead of print - 2 Nov 2019

Bibliographical note

Copyright © 2019 Elsevier Inc. All rights reserved.

ID: 58311047